Dyslipidemia in HIV patients

Area of Science:

• Internal Medicine
• Cardiology
• Infectious Diseases

Background:

• Antiretroviral therapy has improved longevity for individuals with human immunodeficiency virus (HIV).
• Non-HIV related medical conditions, such as dyslipidemia, are becoming increasingly significant in the aging HIV population.
• Dyslipidemia is a modifiable risk factor for cardiovascular disease and has been associated with HIV infection and its treatment.

Purpose of the Study:

• To highlight the growing relevance of dyslipidemia in patients with HIV.
• To emphasize the importance of managing dyslipidemia in HIV-positive individuals, similar to HIV-negative patients.
• To draw attention to potential interactions between lipid-lowering and antiretroviral medications.

Main Methods:

• Literature review and clinical guideline synthesis.
• Analysis of cardiovascular disease risk factors in HIV.
• Discussion of pharmacological considerations for managing dyslipidemia in HIV.

Main Results:

• Dyslipidemia is a prevalent concern in the HIV-infected population undergoing long-term therapy.
• The link between HIV, its treatment, and dyslipidemia necessitates proactive management.
• Cardiovascular risk in HIV patients requires careful assessment and intervention.

Conclusions:

• Managing dyslipidemia in HIV patients is essential for mitigating cardiovascular risk.
• Treatment strategies for dyslipidemia in HIV-positive individuals should mirror those for the general population.
• Close monitoring for drug interactions between antiretrovirals and lipid-lowering agents is critical.